Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-arm, open-label trial study of THX-RS01 in treating Tourette syndrome

Trial Profile

A single-arm, open-label trial study of THX-RS01 in treating Tourette syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dronabinol/palmitoylethanolamide (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 20 Aug 2018 According to a Therapix Biosciences media release, the results were presented at the annual meeting of the European Society for the Study of Tourette Syndrome 2018.
    • 11 Jun 2018 According to Therapix Biosciences Ltd. media release, the results from this study will be presented at the 11th European Society for the Study of Tourette Syndrome (ESSTS) conference in June.
    • 31 May 2018 Status changed from active, no longer recruiting to completed, according to a herapix Biosciences media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top